<DOC>
	<DOCNO>NCT01085318</DOCNO>
	<brief_summary>The purpose trial evaluate effect Rebif® 44 mcg subcutaneous ( sc ) three time week ( tiw ) ) remyelination/demyelination , b ) lesion brain volume , c ) central nervous system ( CNS ) iron deposition , ) immune status subject relapsing-remitting multiple sclerosis ( RRMS ) RRMS via several MRI technique .</brief_summary>
	<brief_title>Rebif Advanced Magnetic Resonance Imaging ( MRI ) Immunology Pilot Trial</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Male female subject , 1865 year age , inclusive , time informed consent signature 2 . RRMS diagnose accord McDonald criterion , treatment naïve currently use FDAapproved DMDs ( exclude natalizumab ( Tysabri® ) , mitoxantrone Rebif® ) 3 . Have disease duration twenty year 4 . Be willing able comply study procedure duration trial 5 . Have give write informed consent sign Health Insurance Portability Accountability Act ( HIPAA ) Authorization study related activity carry 6 . Female subject must either pregnant breastfeeding must lack childbearing potential , define either : The follow inclusion criterion must fulfil Healthy Control subject : 1 . Male female subject , 1865 year age , inclusive , time informed consent signature 2 . Be willing able comply study procedure duration trial 3 . Have give write informed consent sign Health Insurance Portability Accountability Act ( HIPAA ) Authorization study related activity carry 4 . Female subject must either pregnant breastfeeding must lack childbearing potential , define either : 1 . Have receive treatment within three month prior Screening interferonbeta1a ( Rebif® ) , IVIG plasmapheresis 2 . Have receive treatment within thirty day prior screen immunosuppressant agent ( e.g . include limited mitoxantrone , cyclophosphamide , cladribine , fludarabine , cyclosporine total body irradiation ) concomitant immunomodulatory therapy ( e.g. , azathioprine , methotrexate , CellCept® , natalizumab , alemtuzumab/Campath immunomodulators/monoclonal agent ) 3 . Have relapse within thirty day prior Screening Visit 4 . Have receive steroid treatment within thirty day prior initial MRI scan date Study Day 1 5 . Have inadequate liver function , define alanine aminotransferase ( ALT ) &gt; 2.5x upper limit normal ( ULN ) , alkaline phosphatase &gt; 2.5x ULN , total bilirubin &gt; 1.5x ULN 6 . Have inadequate bone marrow reserve , define total white blood cell count &lt; 3.0x 109/L , platelet count &lt; 75x109/L , hemoglobin &lt; 100g/L 7 . Have complete transverse myelitis simultaneousonset bilateral optic neuritis 8 . Have history alcohol drug abuse 9 . Have thyroid dysfunction 10 . Have moderate severe renal impairment 11 . Have major medical psychiatric illness opinion investigator create undue risk subject could affect compliance study protocol 12 . Have history seizure adequately control treatment 13 . Have serious acute cardiac disease , uncontrolled dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure 14 . Have , opinion investigator , visual , physical cognitive impairment would preclude subject comply study protocol 15 . Have know hypersensitivity allergy interferonbeta excipients 16 . Have receive investigational drug experimental procedure within past thirty day 17 . Are pregnant attempt conceive The following exclusion criterion must fulfil Healthy Control subject : 1 . Have meet note criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>